February 16, 2016 — Apervita Inc. announced the American College of Cardiology (ACC) will add a recognized tool for predicting atherosclerotic cardiovascular disease (ASCVD) to the growing body of analytics being distributed through the Apervita Marketplace.
Published jointly with the American Heart Association, ACC's ASCVD Risk Estimator is used as a facilitator for physician-patient discussion about risk reduction through lifestyle change. The popular tool has been downloaded more than 250,000 times and is used more than 7,000 times per day by individual providers, but in its current form requires manual transfer of data between records. The goal of the ACC is to make this tool available to every physician dealing with cardiovascular risk. By offering the risk estimator through Apervita, ACC will now make it available from within electronic health records (EHRs) and other systems that physicians use every day.
The ASCVD Risk Estimator is a companion tool to the 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk and the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. It employs multiple algorithms within one analytic to help address 10-year and lifetime risk for ASCVD, defined as coronary death or nonfatal myocardial infarction, or fatal or nonfatal stroke.
For more information: www.acc.org, www.apervita.com